Disease · MONDO_0021040

pancreatic neoplasm

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. pancreatic neoplasm. Diseases, record MONDO_0021040. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0021040

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: pancreatic neoplasm; Open Targets
Open Targets ID: MONDO_0021040; Open Targets
Other names: NEOPL PANCREATIC, Neoplasia of the pancreas, Neoplasm, Pancreas, Neoplasm, Pancreatic, Neoplasms, Pancreas, Neoplasms, Pancreatic, PANCREAS NEOPL, PANCREATIC NEOPL, Pancreas Neoplasms, Pancreatic Neoplasms, neoplasm of pancreas, neoplasm of the pancreas, pancreas neoplasm, pancreas neoplasm (disease), pancreas tumor, pancreas tumour, pancreatic cancer, pancreatic tumor, pancreatic tumour, tumor of pancreas, tumor of the pancreas, tumour of pancreas, tumour of the pancreas; Open Targets
MeSH: D010190; MeSH
NCI Thesaurus: C3305; NCI Thesaurus
Highest stage of its drugs: Approval, for 15 of its 465 drugs, from ClinicalTrials.gov, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs465

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PACLITAXEL	CHEMBL428647	Small molecule	Approval	EMA Human Drugs	199	195	120	Drugs and targets
FLUOROURACIL	CHEMBL185	Small molecule	Approval	ClinicalTrials.gov	146	146	120	Drugs and targets
OXALIPLATIN	CHEMBL414804	Small molecule	Approval	ClinicalTrials.gov	136	136	110	Drugs and targets
IRINOTECAN HYDROCHLORIDE	CHEMBL3989514	Small molecule	Approval	EMA Human Drugs	38	37	18	Drugs and targets
ERLOTINIB	CHEMBL553	Small molecule	Approval	EMA Human Drugs	23	20	20	Drugs and targets
OLAPARIB	CHEMBL521686	Small molecule	Approval	EMA Human Drugs	15	13	13	Drugs and targets
FOLINIC ACID	CHEMBL1232801	Small molecule	Approval	ClinicalTrials.gov	12	12	10	Drugs and targets
EVEROLIMUS	CHEMBL1908360	Small molecule	Approval	EMA Human Drugs	6	5	5	Drugs and targets
ANAMORELIN HYDROCHLORIDE	CHEMBL2103794	Small molecule	Approval	PMDA	2	1	1	Drugs and targets
ZENOCUTUZUMAB	CHEMBL4298025	Antibody	Approval	FDA	2	0	0	Drugs and targets

1 to 10 of 465

See all 465 drugs

Targets430

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KDR	Vascular endothelial growth factor receptor	21	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3791	Drugs and targets
FLT4	Vascular endothelial growth factor receptor	18	Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2324	Drugs and targets
EGFR	Epidermal growth factor receptor	17	Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor inhibitor	Approval	https://conductscience.org/library/genes/1956	Drugs and targets
FLT1	Vascular endothelial growth factor receptor	17	Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/2321	Drugs and targets
PDCD1	Programmed cell death protein 1	16	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 3	https://conductscience.org/library/genes/5133	Drugs and targets
PDGFRB	Platelet-derived growth factor receptor	15	Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/5159	Drugs and targets
ERBB2	Epidermal growth factor receptor	14	Epidermal growth factor receptor inhibitor; ErbB-2/ErbB-3 heterodimer inhibitor; Receptor protein-tyrosine kinase erbB-2 binding agent; Receptor protein-tyrosine kinase erbB-2 inhibitor	Approval	https://conductscience.org/library/genes/2064	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	14	Stem cell growth factor receptor inhibitor	Phase 3	https://conductscience.org/library/genes/3815	Drugs and targets
TUBA1A	Tubulin	12	Tubulin inhibitor; Tubulin stabiliser	Approval	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	12	Tubulin inhibitor; Tubulin stabiliser	Approval	https://conductscience.org/library/genes/10376	Drugs and targets

1 to 10 of 430

See all 430 targets

Trials753

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 29 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00940225	Study of Cabozantinib (XL184) in Adults With Advanced Malignancies	Phase 2	730	2024-04-25	Solid Tumors, Cancer	CABOZANTINIB	Its record names the disease	ClinicalTrials.gov
NCT00471146	Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.	Phase 3	630	2012-07-16	Carcinoma, Pancreatic Ductal	AXITINIB, GEMCITABINE	Its record names the disease	ClinicalTrials.gov
NCT00574275	Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer	Phase 3	546	2012-09-25	Pancreatic Neoplasm	AFLIBERCEPT, GEMCITABINE	Its record names the disease	ClinicalTrials.gov
NCT01013649	Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery	Phase 3	546	2024-10-24	Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Pancreatic Intraductal Papillary-Mucinous Neoplasm, Stage I Pancreatic Cancer AJCC v6 and v7, Stage II Pancreatic Cancer AJCC v6 and v7	CAPECITABINE, ERLOTINIB HYDROCHLORIDE, FLUOROURACIL, GEMCITABINE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT01631552	Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer	Phase 1/2	515	2021-04-06	Gastric Adenocarcinoma, Esophageal Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Small Cell Lung Cancer, Ovarian Epithelial Cancer, Carcinoma Breast Stage IV, Hormone-refractory Prostate Cancer, Head and Neck Cancers- Squamous Cell, Renal Cell Cancer, Urinary Bladder Neoplasms, Cervical Cancer, Endometrial Cancer, Glioblastoma Multiforme, Triple Negative Breast Cancer, Pancreatic Cancer	SACITUZUMAB GOVITECAN	Its record names the disease	ClinicalTrials.gov
NCT03665441	Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC	Phase 3	512	2022-09-28	Pancreatic Adenocarcinoma	ASPARAGINASE, FLUOROURACIL, GEMCITABINE, IRINOTECAN, IRINOTECAN HYDROCHLORIDE, LEUCOVORIN, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT01494506	Study of MM-398 With or Without 5-FU/LV, Versus 5-FU/LV in Patients With Metastatic Pancreatic Cancer	Phase 3	417	2016-02-12	Metastatic Pancreatic Cancer	FLUOROURACIL, IRINOTECAN, LEUCOVORIN CALCIUM	Its record names the disease	ClinicalTrials.gov
NCT01124786	A Study Comparing CO-1.01 With Gemcitabine as First Line Therapy in Patients With Metastatic Pancreatic Adenocarcinoma (LEAP)	Phase 2	367	2014-04-17	Metastatic Pancreatic Adenocarcinoma	GEMCITABINE, GEMCITABINE ELAIDATE	Its record names the disease	ClinicalTrials.gov
NCT02004262	Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting	Phase 2	303	2018-05-03	2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer	CYCLOPHOSPHAMIDE	Its record names the disease	ClinicalTrials.gov
NCT03941093	Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer	Phase 3	284	2024-11-05	Pancreatic Cancer Non-resectable	FLUOROURACIL, GEMCITABINE, IRINOTECAN, LEUCOVORIN, OXALIPLATIN, PACLITAXEL, PAMREVLUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 753

See all 753 trials

Comparisons in its trials99

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Axitinib + Gemcitabine vs Placebo + Gemcitabine: serious adverse events	108 of 304	102 of 309	613	NCT00471146	Trial comparisons
Placebo and Gemcitabine vs Aflibercept and Gemcitabine: serious adverse events	122 of 271	148 of 270	541	NCT00574275	Trial comparisons
Eryaspase Plus Chemotherapy vs Chemotherapy Alone: Disease Control Rate (DCR)	147 of 255	126 of 257	512	NCT03665441	Trial comparisons
Eryaspase Plus Chemotherapy vs Chemotherapy Alone: Objective Response Rate (ORR)	41 of 255	32 of 257	512	NCT03665441	Trial comparisons
Eryaspase Plus Chemotherapy vs Chemotherapy Alone: deaths from any cause	209 of 248	211 of 246	494	NCT03665441	Trial comparisons
Eryaspase Plus Chemotherapy vs Chemotherapy Alone: serious adverse events	122 of 248	105 of 246	494	NCT03665441	Trial comparisons
Placebo and Gemcitabine vs Aflibercept and Gemcitabine: Number of Participants With Anti-drug Antibodies	5 of 202	5 of 201	403	NCT00574275	Trial comparisons
CO-1.01 vs Gemcitabine: serious adverse events	82 of 179	82 of 181	360	NCT01124786	Trial comparisons
Pamrevlumab + Gemcitabine/Nab-paclitaxel or FOLFIRINOX vs Placebo + Gemcitabine/Nab-paclitaxel or FOLFIRINOX: Number of Participants With Best Overall Objective Response as Assessed Using RECIST v1.1	43 of 143	64 of 141	284	NCT03941093	Trial comparisons
Pamrevlumab + Gemcitabine/Nab-paclitaxel or FOLFIRINOX vs Placebo + Gemcitabine/Nab-paclitaxel or FOLFIRINOX: deaths from any cause	118 of 143	112 of 141	284	NCT03941093	Trial comparisons

1 to 10 of 99

See all 99 comparisons in its trials

Papers from its trials315

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
38957079	RESULT	1	PubMed
38794273	RESULT	1	PubMed
38155512	RESULT	1	PubMed
38126766	RESULT	1	PubMed
38050737	RESULT	1	PubMed
36592507	RESULT	1	PubMed
35843174	RESULT	1	PubMed
35476508	RESULT	2	PubMed
34766118	RESULT	1	PubMed
34288696	RESULT	1	PubMed

1 to 10 of 315

See all 315 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0021040

GET https://conductscience.org/api/diseases/v1/MONDO_0021040/drugs?page=2

API reference For AI assistants